Pharmacotherapeutic options for attention deficit hyperactivity disorder (ADHD)


  • Jarnail Singh Department of Pharmacology, Pt. BD Sharma UHS, Rohtak, Harayana, India



Attention deficit hyperactivity disorder, ADHD, ADR, Stimulants, TCAs


Attention deficit hyperactivity disorder (ADHD), the most common behavioral disorder in children, may disable the patient throughout life. Diagnosis of ADHD is based on DSM-IV-revised criteria. ADHD is a costly health problem and various drugs including stimulants, tricyclic antidepressants (TCAs), bupropion, pemoline, clonidine and atomoxetine have been used to treat it. Atomoxetine and stimulants are the most commonly prescribed drugs for pediatric ADHD with similar efficacy, but serious adverse events with atomoxetine have been reported.

Author Biography

Jarnail Singh, Department of Pharmacology, Pt. BD Sharma UHS, Rohtak, Harayana, India




American academy of pediatrics. Clinical practice guideline: Diagnosis and evaluation of the child with attention-deficit-hyperactivity-disorder. Pediatrics. 2000;105:1158-70.

Attention-deficit/hyperactivity disorder (ADHD). Availabe at html

American psychiatric association. Diagnostic and statistical manual of mental disorders, 4th ed. rev (DSM-IV-R). Washington DC; 2000.

Hille ET, den Quaden AL, Saigal S, Wolke D, Lambert M, Whitaker A, et al. Behavioral problems in children who weigh 1000 g or less at birth in four countries. Lancet. 2001;357:1641-3.

Castellanos FX, Lee PP, Sharp W, Jeffries NO, Greenstein DK, Clasen LS, et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit-hyperactivity disorder. JAMA. 2002;288:1740-8.

Biederman J. Attention-deficit-hyperactivity disorder: A life span perspective. J Clin Psychiatr. 1998;59:4-16.

Jensen PS, Garcia JA, Glied S, Crowe M, Foster M, Schalender M, et al. Cost-effectiveness of ADHD treatments: Findings from the multimodal treatment study of children with ADHD. Am J Psychiatr. 2005;162:1628-36.

Rappley MD. Attention deficit-hyperactivity disorder. N Engl J Med. 2005;352:165-73.

Greydanus DE, Pratt HD, Sloane MA, Pappley MD. Attention-deficit-hyperactivity disorder in children and adolescents: interventions for a complex costly clinical conundrum. Paediatr Clin N Am. 2003; 50:1049-92.

Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial. Pediatr. 1997;100:662-6.

Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, et al. Once daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder; including an assessment of evening and morning behavior: A double blind, placebo-controlled trial. Pediatr. 2004;114:e1-8.

Horrigan JP, Barnhill LJ. Gaunfacine for treatment of attention-deficit hyperactivity disorder in boys. J Child Adolesc Pharmacol. 1995;5:215-23.

Barrickman LL, Perry PJ, Allen AJ, Kuperman S, Arndt Smith, Hermann KJ, et al. Bupropion versus methylphenidate in treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatr. 1995;34:649-57.

UMHS Attention deficit disorder guideline; 2013. Available at: /practiceguides/adhd/adhd.pdf

National Association for Continuing Education. Facts about approved medications for adults with ADHD. Available at DHDtoolkit/patienteducation/medications.pdf

Goodman DW. The black book of ADHD. MBL Communications, Inc; 2009.

Barkley RA. Attention deficit hyperactivity disorder in adults: The latest assessment and treatment strategies. Boston: Jones and Bartlett Publishers; 2010.

Joel L. Young ADHD grown up: A guide to adolescent and adult ADHD. New York: WW Norton & Company; 2007.

Biederman J. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double blind, placebo-controlled, flexible-dose study. Pediatr. 2005;116:e777-84.

Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Psychopharmacol. 2000;10(4):311-20.

Tourrette syndrome study group. Treatment of ADHD in children with tics: a randomised controlled trial. Neurol. 2002;58(4):527-36.

Biederman J, Willens T, Mick E, Spencer T and Faraone S. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk of substance use disorder. Pediatr. 1999;104:e20.

Ramsay JR, Rostain AL. Cognitive behavioral therapy for adult ADHD: An integrative psychosocial and medical approach. New York: Routledge, Taylor and Francis Group; 2008

Solanto MV, Marks DJ, Wasserstein J, Mitchell K, Abikoff H, Alvir JM, et al. Efficacy of Meta-Cognitive Therapy for Adult ADHD. Am J Psychiatr. 2010;167(8):958-68.

Pelham WE, Fabiano GA. Evidence-based psychosocial treatments for attention-deficit/hyperactivity disorder. J Clin Child Adolesc Psychol. 2008;37(1):184-214.

Silva AP, Prado SO, Scardovelli TA, Boschi SR, Campos LC, Frère AF. Measurement of the effect of physical exercise on the concentration of individuals with ADHD. PLoS One. 2015;10(3):e0122119.

Newcorn J, Weiss M, Biederman J. Non-stimulant medications. Medscape education. Availabe at: Assessed July 10, 2013.

Blader JC, Schooler NR, Jensen PS, Pliszka SR, Kafantaris V. Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. Am J Psychiatr. 2009;166 (12):1392-401.




How to Cite

Singh, J. (2017). Pharmacotherapeutic options for attention deficit hyperactivity disorder (ADHD). International Journal of Research in Medical Sciences, 5(11), 4677–4682.



Review Articles